Highly efficient transduction of endothelial cells by targeted artificial virus-like particles

Cancer Gene Therapy

Volumn 8, Issue 2, 2001, Pages 107-117

  Müller, Kristina ^a   Nahde, Thomas ^a   Fahr, Alfred ^a   Müller, Rolf ^a   Brüsselbach, Sabine ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Anionic liposome; Artificial virus like envelope (AVE); Artificial virus like particle (AVP); Cyclic RGD; Endothelial cells; Integrin targeting; Nonviral vectors; Polyethyleneimine

Indexed keywords

BETA3 INTEGRIN; LIPOSOME; PLASMID DNA; POLYETHYLENEIMINE; VIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; TUMOR VASCULARIZATION; VIRUS ENVELOPE; VIRUS PARTICLE;

AVES;

EID: 0035103477     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700280     Document Type: Article

References (52)

1. Delivery of molecular and cellular medicine to solid tumors
2. Fighting cancer by attacking its blood supply
3. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
4. Chemotherapy targeted to tumor vasculature
5. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms
6. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy
7. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells
8. Fibronectin and its integrin receptors in cancer
9. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
10. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an antiangiogenic therapeutic strategy
11. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
12. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
13. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new antiendoglin monoclonal antibodies
14. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
15. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display
16. Liposomes enhance delivery and expression of an RGD-oligolysine gene transfer vector in human tracheal cells
17. Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway
18. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection
19. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector
20. Lipofection: A highly efficient, lipid-mediated DNA transfection procedure
21. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle
22. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethyleneimine
23. Lipidic vector systems for gene transfer
24. The interaction of liposomes with the complement system
25. Gene therapy using HVJ liposomes: The best of both worlds?
26. Artificial viral envelopes containing recombinant human immunodeficiency virus (HIV) gp160
27. Alpha v integrins as receptors for tumor targeting by circulating ligands
28. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells
29. Nonviral gene therapy: The promise of genes as pharmaceutical products
30. New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy
31. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer
32. (Patho)Physiologic pathways to drug targeting: Artificial viral envelopes
33. Improved packing of poly(ethyleneimine)/DNA complexes increases transfection efficiency
34. The proton sponge: A trick to enter cells the viruses did not exploit
35. Cationic liposome-mediated intravenous gene delivery
36. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery
37. Polyethyleneimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells
38. Tracking the intracellular path of poly(ethyleneimine)/DNA complexes for gene delivery
39. A novel nonviral vector for DNA delivery based on low-molecular-weight, branched polyethyleneimine: Effect of molecular weight on transfection efficiency and cytotoxicity
40. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes
41. Uptake of liposomes containing phosphatidylserine by liver cells in vivo and by sinusoidal liver cells in primary culture: In vivo-in vitro differences
42. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium
43. Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement
44. Gene therapy: Designer promoters for tumour targeting
45. Enhancement of the in vivo circulation lifetime of L-alpha-distearoylphosphatidylcholine liposomes: Importance of liposomal aggregation versus complement opsonization
46. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles
47. A new hydrophobic anchor for the attachment of proteins to liposomal membranes
48. Immunofluorescence using dichlorotriazinylaminofluorescein (DTAF): I. Preparation and fractionation of labelled IgG
49. Biophysical aspects of nonviral gene delivery systems
50. Dynamic laser light scattering to determine size distributions of vesicles
51. Human endothelial cells: Use of heparin in cloning and long-term serial cultivation